JP2023536509A - アクアポリン阻害剤の医薬組成物およびその製造方法 - Google Patents

アクアポリン阻害剤の医薬組成物およびその製造方法 Download PDF

Info

Publication number
JP2023536509A
JP2023536509A JP2023508083A JP2023508083A JP2023536509A JP 2023536509 A JP2023536509 A JP 2023536509A JP 2023508083 A JP2023508083 A JP 2023508083A JP 2023508083 A JP2023508083 A JP 2023508083A JP 2023536509 A JP2023536509 A JP 2023536509A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
bis
phenyl
trifluoromethyl
chlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023508083A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023536509A5 (https=
Inventor
チエン，ヨン
シー，ルイウェン
リウ，エイミー
ソン，ティエン
リウ，イェンホン
フォン，アイジュエン
レン，ジンシェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Simcere Pharmaceutical Co Ltd
Aeromics Inc
Original Assignee
Jiangsu Simcere Pharmaceutical Co Ltd
Aeromics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Simcere Pharmaceutical Co Ltd, Aeromics Inc filed Critical Jiangsu Simcere Pharmaceutical Co Ltd
Publication of JP2023536509A publication Critical patent/JP2023536509A/ja
Publication of JP2023536509A5 publication Critical patent/JP2023536509A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023508083A 2020-08-05 2021-08-04 アクアポリン阻害剤の医薬組成物およびその製造方法 Pending JP2023536509A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010779964.6 2020-08-05
CN202010779964 2020-08-05
PCT/CN2021/110506 WO2022028459A1 (en) 2020-08-05 2021-08-04 Pharmaceutical composition of aquaporin inhibitor and preparation method thereof

Publications (2)

Publication Number Publication Date
JP2023536509A true JP2023536509A (ja) 2023-08-25
JP2023536509A5 JP2023536509A5 (https=) 2024-08-06

Family

ID=80120008

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023508083A Pending JP2023536509A (ja) 2020-08-05 2021-08-04 アクアポリン阻害剤の医薬組成物およびその製造方法

Country Status (12)

Country Link
US (1) US20230293556A1 (https=)
EP (1) EP4192442A4 (https=)
JP (1) JP2023536509A (https=)
KR (1) KR20230137284A (https=)
CN (1) CN117337182A (https=)
AU (1) AU2021323181A1 (https=)
BR (1) BR112023002129A2 (https=)
CA (1) CA3187716A1 (https=)
IL (1) IL300341A (https=)
MX (1) MX2023001493A (https=)
TW (1) TW202228714A (https=)
WO (1) WO2022028459A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013169939A2 (en) 2012-05-08 2013-11-14 Aeromics, Llc New methods
US20160279155A1 (en) 2013-11-06 2016-09-29 Aeromics, Inc. Novel formulations
US11117909B2 (en) 2016-05-13 2021-09-14 Aeromics, Inc. Crystals
WO2024208207A1 (zh) * 2023-04-03 2024-10-10 拜西欧斯（北京）生物技术有限公司 一种双取代萘化合物及其药物组合物和用途
WO2025075479A1 (ko) * 2023-10-04 2025-04-10 이화여자대학교 산학협력단 아쿠아포린 4 억제제의 심방세동 치료 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520151A (ja) * 2012-05-08 2015-07-16 エアロミクス・リミテッド・ライアビリティ・カンパニーＡｅｒｏｍｉｃｓ，ＬＬＣ 新規方法
JP2016536370A (ja) * 2013-11-06 2016-11-24 エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． 新規製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2488363C (en) * 2002-06-06 2011-01-04 Institute Of Medicinal Molecular Design, Inc. O-substituted hydroxyaryl derivatives
WO2008067196A2 (en) * 2006-11-16 2008-06-05 The Regents Of The University Of California Methods for identifying inhibitors of solute transporters
CA2931550C (en) * 2013-12-13 2023-09-26 Vertex Pharmaceuticals Incorporated Prodrugs of pyridone amides useful as modulators of sodium channels
US11117909B2 (en) * 2016-05-13 2021-09-14 Aeromics, Inc. Crystals

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520151A (ja) * 2012-05-08 2015-07-16 エアロミクス・リミテッド・ライアビリティ・カンパニーＡｅｒｏｍｉｃｓ，ＬＬＣ 新規方法
JP2016536370A (ja) * 2013-11-06 2016-11-24 エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． 新規製剤

Also Published As

Publication number Publication date
CN117337182A (zh) 2024-01-02
AU2021323181A1 (en) 2023-03-23
IL300341A (en) 2023-04-01
MX2023001493A (es) 2023-06-23
EP4192442A1 (en) 2023-06-14
BR112023002129A2 (pt) 2023-04-18
US20230293556A1 (en) 2023-09-21
TW202228714A (zh) 2022-08-01
CA3187716A1 (en) 2022-02-10
EP4192442A4 (en) 2025-03-19
KR20230137284A (ko) 2023-10-04
WO2022028459A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
JP2023536509A (ja) アクアポリン阻害剤の医薬組成物およびその製造方法
EP2676677B1 (en) Highly concentrated anti-cd40 antibody pharmaceutical preparation
EP4066849B1 (en) Daptomycin formulations and uses thereof
JP7409772B2 (ja) ダントロレンを含む水性組成物
KR20150127256A (ko) 눈의 후안부로의 약물 전달을 위한 안구용 제제
WO2000072873A1 (fr) Preparations lyophilisees de hgf
US11534402B2 (en) Liquid pharmaceutical composition
JPS5978117A (ja) 新規な薬理学的組成物およびその製造方法
JP2018531268A6 (ja) ダントロレンを含む水性組成物
EA036982B1 (ru) Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин с
US20080103121A1 (en) Cephalosporin derivative formulation
KR101468153B1 (ko) 5α-안드로스테인-3β,5,6β-트리올 주사제 및 제조방법
CN117320727A (zh) 低吸附格列本脲制剂及方法
EP3906917B1 (en) Formulations of vancomycin with glycerol
RU2007152C1 (ru) Офтальмологическое средство и способ его получения
KR100807650B1 (ko) Ｎ-[ｏ-(ｐ-피발로일옥시벤젠술포닐아미노)벤조일]글리신·모노나트륨염·4수화물의 동결 건조 제제 및 그 제조 방법
JP2021521232A (ja) メグルミン塩を使用して製剤を含むタンパク質を安定化するための方法
WO2017198224A1 (zh) 一种瑞马唑仑的药物组合物
EA024344B1 (ru) Составы для инфузии лантибиотиков типа b
US20230068866A1 (en) Daptomycin formulation
RS67285B1 (sr) Tečna farmaceutska kompozicija koja ispoljava odličnu efikasnost konzerviranja
JP7423028B2 (ja) ボルテゾミブを含有する凍結乾燥医薬組成物
CN108159005B (zh) 注射剂用组合物
US20130131089A1 (en) Dosage forms of elinogrel and methods of injectable administration thereof
WO2011137459A1 (en) Dosage forms of elinogrel and methods of injectable administration thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240726

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260114